065660.KQ
Anterogen.Co.,Ltd.
KOE · Healthcare · Biotechnology · KR
KRW 14,840.00
−0.34%Year over year
Reported trailing growth
- Revenue
- +16.6%
- EBITDA
- -14.7%
- EBIT
- +29.0%
- EPS
- +20.7%
- Free cash flow
- +37.2%
- Operating cash flow
- +42.8%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +4.6%
- EBITDA
- -14.1%
- EBIT
- +35.1%
- Net income
- +52.3%
- EPS
- +53.2%
- Free cash flow
- +4.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026